An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
2 other identifiers
interventional
481
10 countries
114
Brief Summary
To evaluate the safety and tolerability of afatinib (Giotrif) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKI
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 2013
Longer than P75 for phase_3
114 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 13, 2013
CompletedFirst Posted
Study publicly available on registry
May 15, 2013
CompletedStudy Start
First participant enrolled
July 17, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2024
CompletedResults Posted
Study results publicly available
April 11, 2025
CompletedApril 11, 2025
April 1, 2025
10.6 years
May 13, 2013
February 28, 2025
April 10, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Patients With Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
Number of patients with any treatment emergent adverse event (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
From first drug administration to last drug administration plus 28 days of residual effect period. Up to 3866 days.
Study Arms (1)
Afatinib treated-patients
EXPERIMENTALPatients diagnosed with EGFR mutation positive non-small cell lung cancer (NSCLC) locally advanced or metastatic who have never been treated with EGFR tyrosine kinase inhibitors (TKI) received a daily dose of 40 milligrams (mg) of afatinib (Giotrif®), in the form of film-coated tablet over a 28 day cycle. Afatinib was taken orally with 250 milliliters (mL) of water at the same time of the day and without eating anything for at least 3 hours. Patients continued on treatment for as long as there was no disease progression or no other trial withdrawal criteria. The dose was reduced to 30 mg or 20 mg once daily when the initial dose was not tolerated by the patient.
Interventions
Patients received a daily dose of 40 milligrams (mg) of afatinib (Giotrif®), in the form of film-coated tablet over a 28 day cycle. Afatinib was taken orally with 250 milliliters (mL) of water at the same time of the day and without eating anything for at least 3 hours. Patients continued on treatment for as long as there was no disease progression or no other trial withdrawal criteria. The dose was reduced to 30 mg or 20 mg once daily when the initial dose was not tolerated by the patient.
Eligibility Criteria
You may qualify if:
- Patients with:
- locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.
- Adequate organ function, defined as all of the following:
- Absolute Neutrophil Count (ANC) \> 1500/mm3. (ANC \>1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).
- Platelet count \>75,000/mm3
- Serum creatinine \< 1.5 times of the upper limit of normal
- Total Bilirubin \< 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be \<4 times institutional upper limit of normal).
- Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \< three times the upper limit of (institutional) normal (ULN) (if related to liver metastases \< five times ULN).
- Eastern Cooperative Oncology Group (ECOG) score between 0 - 2
- written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.
You may not qualify if:
- Patients who or with:
- prior treatment with an EGFR tyrosine kinase inhibitor (TKI)
- anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)
- radiotherapy within 14 days prior to drug administration, except as follows:
- Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and
- Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
- previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
- known pre-existing interstitial lung disease
- meningeal carcinomatosis and symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of medication)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (118)
The Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
Sunshine Hospital
AT Albans, Victoria, 3021, Australia
St John of God Murdoch
Murdoch, Western Australia, 6150, Australia
Medical University of Graz State Hospital - University Hospital Graz
Graz, 8036, Austria
Ordensklinikum Linz GmbH - Barmherzige Schwestern
Linz, 4010, Austria
Klinik Penzing SMZ Baumgartner Hoehe
Vienna, 1140, Austria
Klinikum Wels - Grieskirchen GmbH
Wels, 4600, Austria
University Hospital Brno
Brno, 625 00, Czechia
Hospital Hradec Kralove
Hradec Králové, 500 05, Czechia
University Hospital Ostrava
Ostrava, 708 52, Czechia
University Hospital Plzen, Plzen-Bory
Pilsen, 305 00, Czechia
Chest Hospital of Athens "Sotiria"
Athens, 11527, Greece
Metropolitan Hospital, Oncology Clinic
N. Faliro, 18547, Greece
General Oncology Hospital "Agioi Anargyri"
Nea Kifissia, 14564, Greece
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, 57010, Greece
Koranyi National Institute For Pulmonolgy
Budapest, 1121, Hungary
Institute of Chest Diseases Csongrad County,Dpt. Pulmonology
Deszk, 6772, Hungary
Pulmonology Institute of Veszprem County, Farkasgyepu
Farkasgyepü, 8582, Hungary
Fejer County Saint George University Teaching Hospital
Székesfehérvár, 8000, Hungary
Soroka Univ. Medical Center
Beersheba, 84101, Israel
Meir Medical Center
Kfar Saba, 44281, Israel
Rabin Medical Center Beilinson
Petah Tikva, 4941492, Israel
Sourasky Medical Center
Tel Aviv, 64239, Israel
The Chaim Sheba Medical Center Tel HaShomer
Tel Litwinsky, 52621, Israel
Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo
Alessandria, 15100, Italy
Az. Ospedaliere Umberto I di Ancona
Ancona, 60020, Italy
A. O. Giuseppe Moscati
Avellino, 83100, Italy
Centro di riferimento Oncologico
Aviano (PN), 33081, Italy
Istituto Tumori Giovanni Paolo II
Bari, 70124, Italy
A. O. Ospedali Riuniti di Bergamo
Bergamo, 24127, Italy
Policlinico S. Orsola Malpighi
Bologna, 40138, Italy
Ospedale Centrale di Bolzano
Bolzano, 39100, Italy
A.O. Spedali Civili di Brescia
Brescia, 25123, Italy
Azienda Ospedaliera Careggi
Florence, 50139, Italy
Azienda Ospedaliera San Martino
Genova, 16132, Italy
Osp. S. Maria della Scaletta
Imola, 40026, Italy
Azienda Ospedaliera Vito Fazzi
Lecce, 73100, Italy
Osp. Campo di Marte
Lucca, 55100, Italy
Istituto Scientifico Romagnolo
Meldola (FC), 47014, Italy
IRCCS Fondazione Ospedale Maggiore
Milan, 20122, Italy
IRCCS San Raffaele
Milan, 20132, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
Istituto Europeo di Oncologia
Milan, 20141, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
Università di Modena e Reggio Emilia
Modena, 41100, Italy
A.O. San Gerardo di Monza
Monza (MI), 20052, Italy
Istituto Nazionale IRCCS Tumori Fondazione Pascale
Napoli, 80131, Italy
Osp. dei Colli Monaldi-Cotugno
Napoli, 80131, Italy
A.O.U. Maggiore della Carita'
Novara, 28100, Italy
Azienda Sanitaria Ospedale S. Luigi Gonzaga
Orbassano (TO), 10043, Italy
Istituto Oncologico Veneto IRCCS
Padua, 35128, Italy
A.O. Univ. Policlinico "Paolo Giaccone"
Palermo, 90127, Italy
Casa di Cura La Maddalena
Palermo, 90146, Italy
Azienda Ospedaliera di Parma
Parma, 43100, Italy
Ospedale S.Maria della Misericordia, AO di Perugia
Perugia, 06132, Italy
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126, Italy
Ospedale S. Maria delle Croci
Ravenna, 48121, Italy
Irccs Crob
Rionero in Vulture (PZ), 85028, Italy
Università Campus Bio-Medico - ROMA
Roma, 00128, Italy
Istittuo Nazionale Tumori Regina Elena - IRCCS
Roma, 00144, Italy
A.O. San Camillo Forlanini
Roma, 00152, Italy
Poli Univ A. Gemelli
Roma, 00168, Italy
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
Roma, 00189, Italy
Azienda Ospedaliera "Santo Maria"
Terni, 05100, Italy
AO Città della Salute e Scienza
Torino, 10129, Italy
Ospedale S. Maria di Ca' Foncello Azienda ULSS9 TREVISO
Treviso, 31100, Italy
A. O. S. Maria della Misericordia
Udine, 33100, Italy
Ospedale Policlinico G.B. Rossi (Borgo Roma) di Verona
Verona, 37126, Italy
Oncology Center na F. Lukaszczyka
Bydgoszcz, 85-796, Poland
University Clinical Center, Gdansk
Gdansk, 80-952, Poland
Provincial Specialist M. Kopernik Hospital
Lodz, 93-513, Poland
MS Clinsearch, Private Practice
Lublin, 20-090, Poland
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, 60-693, Poland
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, 02-781, Poland
ULS de Coimbra, E.P.E.
Coimbra, 3041-801, Portugal
IPO Lisboa Francisco Gentil, EPE
Lisbon, 1099-023, Portugal
Centro Hospitalar Lisboa Norte Hospital Pulido Valente
Lisbon, 1769-001, Portugal
IPO Porto Francisco Gentil, EPE
Porto, 4200-072, Portugal
ULS de Gaia/Espinho, EPE
Vila Nova de Gaia, 4434-502, Portugal
St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"
Kazan', 420029, Russia
Moscow City Oncology Dispensary, Moscow
Moscow, 111033, Russia
FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF
Moscow, 115478, Russia
Clinical Oncology Center
Omsk, 640 013, Russia
St. Petersburg GUZ City Clinical Oncology Dispensary
Saint Petersburg, 197022, Russia
FSBI "N.N. Petrov National Medical Research Center of Oncology" of MoH of RF
Saint Petersburg, 197758, Russia
Hospital A Coruña
A Coruña, 15006, Spain
Hospital General Universitario de Alicante
Alicante, 03010, Spain
Hospital Germans Trias i Pujol
Badalona, 08916, Spain
Hospital Universitario de Cruces
Barakaldo (Bilbao), 48903, Spain
Hospital del Mar
Barcelona, 08003, Spain
Hospital Vall d'Hebron
Barcelona, 08035, Spain
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Hospital Santa Creu i Sant Pau
Barcelona, 08041, Spain
Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
Hospital Duran i Reynals
L'Hospitalet de Llobregat, 08908, Spain
Hospital de Canarias
La Laguna - Tenerife, 38320, Spain
Hospital La Princesa
Madrid, 28006, Spain
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
Hospital Ramón y Cajal
Madrid, 28034, Spain
Fundación Jiménez Díaz
Madrid, 28040, Spain
Hospital Clínico San Carlos
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital La Paz
Madrid, 28046, Spain
Hospital Puerta de Hierro
Majadahonda (Madrid), 28222, Spain
Hospital Regional Universitario de Málaga
Málaga, 29010, Spain
Hospital Virgen de la Victoria
Málaga, 29010, Spain
Hospital Central de Asturias
Oviedo, 33011, Spain
Hospital Son Espases
Palma de Mallorca, 07120, Spain
Hospital de Son Llàtzer
Palma de Mallorca, 07198, Spain
Complejo Hospitalario de Navarra
Pamplona, 31008, Spain
Hospital Clínico de Santiago
Santiago de Compostela, 15706, Spain
Hospital Virgen del Rocío
Seville, 41013, Spain
Hospital Politècnic La Fe
Valencia, 46009, Spain
Hospital Clínico de Valencia
Valencia, 46010, Spain
Hospital General Universitario de Valencia
Valencia, 46014, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, 50009, Spain
Hospital Miguel Servet
Zaragoza, 50009, Spain
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Boehringer Ingelheim, Call Center
- Organization
- Boehringer Ingelheim
Study Officials
- STUDY CHAIR
Boehringer Ingelheim
Boehringer Ingelheim
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 13, 2013
First Posted
May 15, 2013
Study Start
July 17, 2013
Primary Completion
March 6, 2024
Study Completion
March 6, 2024
Last Updated
April 11, 2025
Results First Posted
April 11, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
- Access Criteria
- For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.